Northwire Canada EditionFriday, July 10, 2026

Sign in Subscribe

FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4%

Regulatory Admin

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

By The Northwire Desk — AI Analysis May 20, 2026 · 16:49 BLCO · 22.21 BAUSCH + LOMB CORPORATION

BLCO · Price

Executive Summary

Bausch + Lomb Corporation announced the election of 10 directors at its 2026 annual meeting of shareholders.
Shareholders approved a non-binding advisory vote regarding the compensation of the Company’s named executive officers.
Shareholders appointed PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm until the close of the 2027 annual meeting.

Key Details

Director Election Results (For / Against / Broker Non-Votes):
- Eduardo Alfonso, M.D.: 331,573,622 / 4,244,069 / 11,452,072
- Nathalie Bernier: 331,522,655 / 4,295,036 / 11,452,072
- Steven H. Collis: 331,575,559 / 4,242,132 / 11,452,072
- Sarah B. Kavanagh: 331,548,740 / 4,268,951 / 11,452,072
- Karen L. Ling: 331,533,402 / 4,284,289 / 11,452,072
- John A. Paulson: 331,537,843 / 4,279,848 / 11,452,072
- Russel C. Robertson: 331,561,696 / 4,255,995 / 11,452,072
- Thomas W. Ross, Sr.: 331,556,884 / 4,260,807 / 11,452,072
- Brenton L. Saunders: 331,476,725 / 4,340,966 / 11,452,072
- Andrew C. von Eschenbach, M.D.: 331,499,049 / 4,318,642 / 11,452,072

Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other Jun 01, 2026 · 06:59

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

Financings May 21, 2026 · 07:15

Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Other May 19, 2026 · 07:00

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

Other May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other May 06, 2026 · 07:15

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise